What is Decitabine Drug Market?
It is estimated that more than 10,000 new cases of myelodysplastic syndrome(MDS) occur in the United States annually. Decitabine is an anti-cancer chemotherapy drug used for the treatment of myelodysplastic syndrome (certain types of blood or bone marrow cancer). It is a class of medications called hypomethylation agents that helps the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The factors such as Increased Prevalence of Myelodysplastic Syndrome among People, Development of New Diagnostic Centres and Hospitals and Increase in Healthcare Expenditure in Developing Regions such as India and China are driving the global decitabine drug market.
The market study is being classified by Type (Prescription and Over-the-Counter), by Application (Myelodysplastic syndrome and Acute Myeloid Leukemia) and major geographies with country level break-up.
ScinoPharm (Taiwan), Otsuka Pharmaceutical Co., Ltd. (Japan), Sandoz (Germany), Dr. Reddy's Laboratories (India), Midas Pharma GmbH (Germany), LGM Pharma (United States), Astex Therapeutics (United States), Accord Healthcare Ltd. (United Kingdom), Sun Pharmaceutical Industries Ltd. (India) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Beijing Lunarsun Pharmaceutical Co., Ltd. (China), Lupin (India), Taj Pharmaceuticals Limited (India) and Innopharma, Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Indian Players will contribute to the maximum growth of Global Decitabine Drug market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Decitabine Drug market by Type, Application and Region.
On the basis of geography, the market of Decitabine Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Myelodysplastic Syndrome among People
- Development of New Diagnostic Centres and Hospitals
- Increase in Healthcare Expenditure in Developing Regions such as India and China
- Increasing Government Funding for the Cancer Research
- Adoption of Novel Technologies By Manufacturers
- Side Effects of the Decitabine Drug
- Huge Investments by Major Players
- Increased Research and Development Investment
- Growth in the Healthcare Industry
- Stringent Government Rules and Regulations
Market Leaders and some development strategies
In June 2020, Dr. Reddy's Laboratories Ltd. has announced that it has completed the acquisition of select divisions of Wockhardt Limitedís branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.
Key Target AudienceDecitabine Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase